文献速递帕金森病与运动障碍

抗α-突触核蛋白单克隆抗体PRX002/RG7935在帕金森病患者中的多剂量递增安全性及耐受性:一项随机临床试验

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项多中心、随机、双盲、安慰剂对照、多剂量递增试验纳入80例轻中度特发性帕金森病患者,评估PRX002(0.3至60 mg/kg)每4周静脉输注3次的安全性。PRX002总体安全且耐受良好,未报告严重或重度相关不良事件,未检出抗药抗体,血清游离α-突触核蛋白较安慰剂最多降低97%。

要点

  • PRX002总体安全且耐受良好,未报告严重或重度相关治疗中出现的不良事件。
  • 至少5%接受PRX002患者发生的不良事件包括便秘9.1%、输注反应7.3%、腹泻5.5%、头痛5.5%、外周水肿5.5%、腰穿后综合征5.5%和上呼吸道感染5.5%。
  • 最高剂量单次输注后血清游离α-突触核蛋白较安慰剂最多降低97%,脑脊液PRX002浓度约为血清的0.3%。

核心结论

  • 单次和多次给予PRX002总体安全且耐受良好,可强效结合外周α-突触核蛋白,并使脑脊液PRX002浓度呈剂量依赖性升高,达到可能结合脑内细胞外聚集α-突触核蛋白的浓度。
  • 研究结果支持正在进行的2期临床研究(NCT03100149)的设计。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、多剂量递增试验,2014年7月至2016年9月在美国8个研究中心开展。
  • 纳入80例40至80岁、轻中度特发性帕金森病(Hoehn和Yahr分期1-3期)患者,随机分配至6个递增剂量队列接受PRX002(0.3 mg/kg、1.0 mg/kg、3.0 mg/kg、10 mg/kg、30 mg/kg或60 mg/kg)或安慰剂。
  • 受试者每4周接受3次静脉输注,并进行24周观察期监测。

主要发现

  • 80例参与者中大多数为白人(97.5%;n=78)和男性(80%;n=64),中位(标准差)年龄为58(8.4)岁。
  • 未报告严重或重度PRX002相关治疗中出现的不良事件(TEAE),未检出抗药抗体。
  • 至少5%接受PRX002患者发生的TEAE(不论与研究药物相关性)包括便秘(9.1%;n=5)、输注反应(7.3%;n=4)、腹泻(5.5%;n=3)、头痛(5.5%;n=3)、外周水肿(5.5%;n=3)、腰穿后综合征(5.5%;n=3)和上呼吸道感染(5.5%;n=3)。
  • 血清PRX002水平呈近似剂量比例升高,平均终末消除半衰期在各剂量间相似(10.2天)。
  • 最高剂量单次输注后,血清游离α-突触核蛋白较基线相对安慰剂呈快速剂量和时间依赖性平均降低,最多达97%(F78,284=1.66;P=.002),再输注2次后降低程度相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Aggregated α-synuclein is believed to be central to the pathogenesis of Parkinson disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed to target aggregated forms of α-synuclein, thereby inhibiting neuron-to-neuron transfer of presumed pathogenic forms of α-synuclein, potentially resulting in neuronal protection and slowing disease progression. OBJECTIVE: To evaluate the safety and tolerability of multiple intravenous infusions of PRX002 in patients with idiopathic PD. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled, multiple ascending-dose trial at 8 US study centers from July 2014 to September 2016. Eligible participants were aged 40 to 80 years with mild to moderate idiopathic PD (Hoehn and Yahr stages 1-3). INTERVENTIONS: Participants were enrolled into 6 ascending-dose cohorts and randomly assigned to receive PRX002 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg, 30 mg/kg, or 60 mg/kg) or placebo. Participants received 3 intravenous infusions every 4 weeks of PRX002 or placebo and were monitored during a 24-week observational period. MAIN OUTCOMES AND MEASURES: Safety and tolerability assessments included physical and neurological examinations, laboratory tests, vital signs, and adverse events. Pharmacokinetic parameters included maximum PRX002 concentration, area under the curve, and half-life. RESULTS: Of the 80 participants, most were white (97.5%; n = 78) and male (80%; n = 64); median (SD) age was 58 (8.4) years. PRX002 was generally safe and well tolerated; no serious or severe PRX002-related treatment-emergent adverse events (TEAEs) were reported. The TEAEs experienced by at least 5% of patients receiving PRX002, irrespective of relatedness to study drug, were constipation (9.1%; n = 5), infusion reaction (7.3%; n = 4), diarrhea (5.5%; n = 3), headache (5.5%; n = 3), peripheral edema (5.5%; n = 3), post-lumbar puncture syndrome (5.5%; n = 3), and upper respiratory tract infection (5.5%; n = 3). No antidrug antibodies were detected. Serum PRX002 levels increased in an approximately dose-proportional manner; mean terminal elimination half-life was similar across all doses (10.2 days). Rapid dose- and time-dependent mean reductions from baseline vs placebo in free serum α-synuclein levels of up to 97% were seen after a single infusion at the highest dose (F78,284 = 1.66; P = .002), with similar reductions after 2 additional infusions. Mean cerebrospinal fluid PRX002 concentration increased with PRX002 dose and was approximately 0.3% relative to serum across all dose cohorts. CONCLUSIONS AND RELEVANCE: Single and multiple doses of PRX002 were generally safe and well tolerated and resulted in robust binding of peripheral α-synuclein and dose-dependent increases of PRX002 in cerebrospinal fluid, reaching cerebrospinal fluid concentrations that may be expected to engage extracellular aggregated α-synuclein in the brain. Findings support the design of an ongoing phase 2 clinical study (NCT03100149). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02157714.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jankovic J, Goodman I, Safirstein B, et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29913017. doi:10.1001/jamaneurol.2018.1487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。